

# Lars Weidolf

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5800964/publications.pdf>

Version: 2024-02-01

32  
papers

2,461  
citations

331670

21  
h-index

377865

34  
g-index

34  
all docs

34  
docs citations

34  
times ranked

2719  
citing authors

#	ARTICLE	IF	CITATIONS
1	COMPARISON OF INHIBITORY EFFECTS OF THE PROTON PUMP-INHIBITING DRUGS OMEPRAZOLE, ESOMEPRAZOLE, LANSOPRAZOLE, PANTOPRAZOLE, AND RABEPRAZOLE ON HUMAN CYTOCHROME P450 ACTIVITIES. <i>Drug Metabolism and Disposition</i> , 2004, 32, 821-827.	3.3	568
2	Use of Radiolabeled Compounds in Drug Metabolism and Pharmacokinetic Studies. <i>Chemical Research in Toxicology</i> , 2012, 25, 532-542.	3.3	226
3	Pharmacokinetic Studies with Esomeprazole, the (S)-Isomer of Omeprazole. <i>Clinical Pharmacokinetics</i> , 2001, 40, 411-426.	3.5	204
4	In Vitro Approach to Assess the Potential for Risk of Idiosyncratic Adverse Reactions Caused by Candidate Drugs. <i>Chemical Research in Toxicology</i> , 2012, 25, 1616-1632.	3.3	197
5	Comparison between electrochemistry/mass spectrometry and cytochrome P450 catalyzed oxidation reactions. <i>Rapid Communications in Mass Spectrometry</i> , 2003, 17, 800-810.	1.5	180
6	State-of-the-art Tools for Computational Site of Metabolism Predictions: Comparative Analysis, Mechanical Insights, and Future Applications. <i>Drug Metabolism Reviews</i> , 2007, 39, 61-86.	3.6	125
7	Risk assessment and mitigation strategies for reactive metabolites in drug discovery and development. <i>Chemico-Biological Interactions</i> , 2011, 192, 65-71.	4.0	90
8	Stereoselective Disposition of Proton??Pump Inhibitors. <i>Clinical Drug Investigation</i> , 2008, 28, 263-279.	2.2	77
9	Cytochrome P450-mediated activation of the fragrance compound geraniol forms potent contact allergens. <i>Toxicology and Applied Pharmacology</i> , 2008, 233, 308-313.	2.8	69
10	In Vitro Metabolism of Haloperidol and Sila-Haloperidol: New Metabolic Pathways Resulting from Carbon/Silicon Exchange. <i>Drug Metabolism and Disposition</i> , 2010, 38, 73-83.	3.3	68
11	Novel Metabolites of Amodiaquine Formed by CYP1A1 and CYP1B1: Structure Elucidation Using Electrochemistry, Mass Spectrometry, and NMR. <i>Drug Metabolism and Disposition</i> , 2009, 37, 571-579.	3.3	67
12	In Vitro Evaluation of Major In Vivo Drug Metabolic Pathways Using Primary Human Hepatocytes and HepaRG Cells in Suspension and a Dynamic Three-Dimensional Bioreactor System. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2012, 343, 134-144.	2.5	55
13	Electrochemical Generation of Electrophilic Drug Metabolites: Characterization of Amodiaquine Quinoneimine and Cysteinyl Conjugates by MS, IR, and NMR. <i>Chemical Research in Toxicology</i> , 2008, 21, 928-935.	3.3	54
14	Metabolism of Xenobiotic Carboxylic Acids: Focus on Coenzyme A Conjugation, Reactivity, and Interference with Lipid Metabolism. <i>Chemical Research in Toxicology</i> , 2013, 26, 1139-1155.	3.3	53
15	Significantly Different Covalent Binding of Oxidative Metabolites, Acyl Glucuronides, and S-Acyl CoA Conjugates Formed from Xenobiotic Carboxylic Acids in Human Liver Microsomes. <i>Chemical Research in Toxicology</i> , 2015, 28, 886-896.	3.3	46
16	Enantiomer/Enantiomer Interactions between the S- and R- Isomers of Omeprazole in Human Cytochrome P450 Enzymes: Major Role of CYP2C19 and CYP3A4. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2005, 315, 777-787.	2.5	43
17	Drug metabolism and pharmacokinetic strategies for oligonucleotide- and mRNA-based drug development. <i>Drug Discovery Today</i> , 2018, 23, 1733-1745.	6.4	40
18	Structural and mechanistic aspects of transcriptional induction of cytochrome P450 1A1 by benzimidazole derivatives in rat hepatoma H4IIE cells. <i>FEBS Journal</i> , 1999, 261, 66-71.	0.2	37

#	ARTICLE	IF	CITATIONS
19	Electrochemical generation of drug metabolites with applications in drug discovery and development. <i>TrAC - Trends in Analytical Chemistry</i> , 2015, 70, 92-99.	11.4	35
20	Sensitive sulphur-specific detection of omeprazole metabolites in rat urine by high-performance liquid chromatography/inductively coupled plasma mass spectrometry. <i>Rapid Communications in Mass Spectrometry</i> , 2004, 18, 181-183.	1.5	33
21	Hip To Be Square: Oxetanes as Design Elements To Alter Metabolic Pathways. <i>Journal of Medicinal Chemistry</i> , 2019, 62, 7383-7399.	6.4	30
22	Oxetane Substrates of Human Microsomal Epoxide Hydrolase. <i>Drug Metabolism and Disposition</i> , 2017, 45, 966-973.	3.3	19
23	Distribution and biotransformation of therapeutic antisense oligonucleotides and conjugates. <i>Drug Discovery Today</i> , 2021, 26, 2244-2258.	6.4	17
24	Bimodal column switching liquid chromatographic assay of six metabolites of [14C] felodipine in rat urine. <i>Biomedical Applications</i> , 1985, 343, 85-97.	1.7	16
25	Study of the electrospray ionization mass spectrometry of the proton pump inhibiting drug Omeprazole. <i>Rapid Communications in Mass Spectrometry</i> , 2001, 15, 283-290.	1.5	16
26	Troglitazone metabolism and transporter effects in chimeric mice: a comparison between chimeric humanized and chimeric murinized FRG mice. <i>Xenobiotica</i> , 2014, 44, 186-195.	1.1	16
27	Discovery of a Novel Microsomal Epoxide Hydrolase-Catalyzed Hydration of a Spiro Oxetane. <i>Drug Metabolism and Disposition</i> , 2016, 44, 1341-1348.	3.3	16
28	Metabolism of Strained Rings: Glutathione <i>S</i> -transferase-Catalyzed Formation of a Glutathione-Conjugated Spiro-azetidine without Prior Bioactivation. <i>Drug Metabolism and Disposition</i> , 2019, 47, 1247-1256.	3.3	14
29	Systemic Exposure to the Metabolites of Lesogaberan in Humans and Animals: A Case Study of Metabolites in Safety Testing. <i>Drug Metabolism and Disposition</i> , 2014, 42, 1016-1021.	3.3	12
30	The metabolic fate of fenclozic acid in chimeric mice with a humanized liver. <i>Archives of Toxicology</i> , 2018, 92, 2819-2828.	4.2	11
31	Qualification of impurities based on metabolite data. <i>Regulatory Toxicology and Pharmacology</i> , 2020, 110, 104524.	2.7	10
32	Database Extraction of Metabolite Information of Drug Candidates: Analysis of 27 AstraZeneca Compounds with Human Absorption, Distribution, Metabolism, and Excretion Data. <i>Drug Metabolism and Disposition</i> , 2016, 44, 732-740.	3.3	9